Digital Therapeutic Company pioneer My mhealth announces successful rollout of NHS approved diabetes app to Kent community

0


Digital Therapeutic Company pioneer My mhealth announces successful rollout of NHS approved diabetes app to Kent community

The largest ever deployment of a digital diabetes therapy program was considered a success in providing 100,000 people in Kent with access to cutting-edge technology.

Monday May 10, 2021 – LONDON, United Kingdom: Today my mhealth announces the successful deployment of its NHS-approved digital diabetes therapy platform, myDiabetes, as 100,000 diabetic patients and their clinics in Kent and Medway can now access the many healthcare benefits health and better manage their conditions from the free app.

Since the highly anticipated launch of the deployment in early April 2021, more than 400 patients have already had access to the myDiabetes platform, these patients having access to more than 350 training sessions. In a complete change in the way patients can interact with their clinician, patients are accessed by their healthcare professional and are then asked to fill in their details such as their blood sugar or BMI to support service delivery. This will directly improve patient care by providing greater accessibility to their most important medical information.

With diabetes affecting around 1 in 14 (4.8 million) people in the UK1, it is essential that support services bring patients and their clinicians closer together while giving them greater control over their own health care. The myDiabetes app was designed to allow patients to self-manage their condition with a user-friendly digital program that provides quick and easy access on smartphones, tablets and computers from anywhere, anytime. The app also offers a unique exercise and dietary intervention program, DMFit, to help patients increase activity and improve nutrition literacy.

In addition, the content of the app is specially designed to allow patients to monitor their blood sugar, HbA1C and other risk factors and access to a specialized training program allows them to learn about their conditions in an attempt to reduce their risk of serious disease in the long term. complications over time. This project will also generate a lot of invaluable information about the needs of patients and how best to support them in the future.

Following the successful deployment of Kent, my mhealth plans to roll out the myDiabetes app to 30 additional clinical departments by the end of 2021.

Global Transformation Lead for my mhealth, Ian Thompson said:

“Diabetes education is an essential component of patient care. The more a person knows about their diabetes, the better able they are to manage their condition and the risk of developing other complications. It is exciting for us to work closely with several diabetes teams. throughout Kent and Medway. “

Kent & Medway Diabetes & CVD Transformation and Development Manager, Ian Butcher commented:

“All of us here at the CCG alongside the Paul Carr Diabetes Trust think this is a really fantastic step forward for people with diabetes in Kent. It is important that we continue to evolve services to ensure we make the best care available. MyDiabetes provides an easy-to-use digital self-management tool, with access to an education program, targeted evidence-based information and counseling. It is designed to complement our existing diabetes services and gives all who use it digital access to tools to better manage their condition for the overall improvement of their health and well-being. “

Gary Fagg MBE, President of the Paula Carr Diabetes Trust, commented:

“The Paula Carr Diabetes Trust is proud to invest in a partnership with Kent & Medway CCG and my mhealth at this very important time for the NHS. We know first-hand the challenges diabetic patients face in accessing services. Providing the digital diabetes platform, myDiabetes, offers a significant breakthrough in continuing education and access to services for our diabetic patients across the region. ”



Source link

Leave A Reply

Your email address will not be published.